2-甲基-4-噻唑乙酰胺 | 185623-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-甲基-4-噻唑乙酰胺
• 中文别名: 2-(2-甲基-4-噻唑)-乙酰胺
• 英文名称: (2-methyl-thiazol-4-yl)-acetic acid amide
• 英文别名: (2-Methyl-thiazol-4-yl)-essigsaeure-amid；2-(2-Methyl-1,3-thiazol-4-yl)acetamide
• CAS: 185623-66-9
• 化学式: C₆H₈N₂OS
• mdl: MFCD03011393
• 分子量: 156.208
• InChiKey: QSGPRSNMQHVIHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险类别码：
  R36
• 海关编码：
  2934100090
• 危险类别：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-甲基-4-噻唑乙酰胺 在 氨 、 镍 、 三氯氧磷 作用下， 110.0~130.0 ℃ 、7.35 MPa 条件下， 生成 2-(2-甲基-1,3-噻唑-4-基)乙胺
  参考文献：
  名称：

  镇痛研究；吡啶和噻唑的β-乙基和β-异丙基胺衍生物。

  摘要：

  DOI：

  10.1021/jo01166a021
• 作为产物：
  描述：

  2-甲基-4-噻唑乙酸乙酯 在 ammonium hydroxide 作用下， 生成 2-甲基-4-噻唑乙酰胺
  参考文献：
  名称：

  镇痛研究；吡啶和噻唑的β-乙基和β-异丙基胺衍生物。

  摘要：

  DOI：

  10.1021/jo01166a021

文献信息

• [EN] PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS<br/>[FR] ANALOGUES DE PURINE ET DE 3-DÉAZAPURINE EN TANT QU'INHIBITEURS DE LA CHOLINE KINASE
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2018019681A1

  公开（公告）日：2018-02-01

  There are provided substituted purine and 3-deazapurine analogues, which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, such as cancer, cell proliferative disorders, infectious diseases of different origin, immune-related disorders and neurodegenerative disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  本发明提供了替代嘌呤和3-去氨基嘌呤类似物，可以调节胆碱激酶（ChoK）的活性。因此，本发明的化合物在治疗由改变的胆碱代谢引起的疾病方面是有用的，如癌症、细胞增殖紊乱、不同起源的传染病、免疫相关疾病和神经退行性疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物、以及利用包含这些化合物的药物组合物治疗疾病的方法。
• [EN] IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] IMIDAZOLYLE DIPHÉNYLE IMIDAZOLES INHIBITRICES DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009102325A1

  公开（公告）日：2009-08-20

  The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

  本公开涉及化合物式（I），组合物以及用于治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这种化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• 3-Carbamoyl-2-Pyridone Derivative
  申请人：Ishizuka Natsuki

  公开号：US20080103139A1

  公开（公告）日：2008-05-01

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 is optionally substituted C1-C8 alkyl and the like; R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl and the like; or R 2 and R 3 taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R 4 is hydrogen and the like; G is a group selected from the groups shown by the formula an the like: wherein R 5 is hydrogen and the like; X 1 is a single bond and the like; X 2 is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R 6 )—, wherein R 6 is hydrogen and the like, and the like; X 3 is a single bond and the like; a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的作用的化合物，其由式（I）表示：其中，R1是可选取的取代的C1-C8烷基等；R2是C1-C6烷基；R3是C1-C6烷基等；或R2和R3共同形成可选取代的5至10个成员的非芳香碳环；R4是氢等；G是由式等所示的基团中选取的基团：其中，R5是氢等；X1是单键等；X2是可选取代的C1-C8烷基，可以被一或两个-O-或-N（R6）-的基团替代，其中R6是氢等；X3是单键等；其药学上可接受的盐或其溶剂，以及制药组合物、治疗特应性皮炎的制剂和抗瘙痒剂，特别是口服和外用的抗瘙痒剂，每种制剂均以所述化合物为活性成分。
• 3-CARBAMOYL-2-PYRIDONE DERIVATIVES
  申请人：ISHIZUKA Natsuki

  公开号：US20120208813A1

  公开（公告）日：2012-08-16

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 , R 2 , R 3 , R 4 , and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的活性的化合物，该受体由公式（I）表示：其中R1、R2、R3、R4和G如本文所定义，其药学上可接受的盐或溶剂，以及制备该化合物为活性成分的药物组合物、治疗特应性皮炎的药剂和抗瘙痒剂，尤其是用于口服和外用的抗瘙痒剂。
• Substituted Azaheterocycles for the Treatment of Cancer
  申请人：Heinrich Timo

  公开号：US20140221366A1

  公开（公告）日：2014-08-07

  The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  本发明提供了一种根据式（I）提供的新型取代的杂氮杂环化合物，其制备和用于治疗过度增殖性疾病，如癌症。